DGAP-News: R-Biopharm AG to collaborate with HMNC Brain

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Apr 19, 2016 at 3:15 AM

DGAP-News: R-Biopharm AG to collaborate with HMNC Brain Health on complementary diagnostic test for optimization of depression treatment

DGAP-News: R-Biopharm AG / Key word(s): Alliance/Miscellaneous R-Biopharm AG to collaborate with HMNC Brain Health on complementary diagnostic test for optimization of depression treatment 19.04.2016 / 09:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- R-Biopharm AG to collaborate with HMNC Brain Health on complementary diagnostic test for optimization of depression treatment Darmstadt, Germany, April 19, 2016 - R-Biopharm AG announced today it has entered into a collaboration agreement with HMNC Brain Health in the field of complementary diagnostics. Under this agreement R-Biopharm AG will develop an in vitro PCR (Polymerase Chain Reaction) based genetic test. The goal is to identify ABCB1 gene variants in patients who are treated with antidepressants in order to optimize the efficacy of depression therapy. The collaboration includes the development, regulatory approval, manufacturing and commercialization of the ABCB1 test. "Complementary diagnostics play a central role in delivering tools that help identifying those individuals who are most likely to benefit from specific treatments" said Dr. Frank Apostel, Vice President Companion Diagnostics, R-Biopharm AG. "We are delighted about this agreement as it expands our service in the field of personalized healthcare. Our goal is to help patients and their physicians to determine the best treatment option available." "A laboratory test that supports the physician in his treatment decision to choose the best drug and the appropriate dose for the individual patient represents a major improvement in antidepressant treatment." states Professor Florian Holsboer, CEO of HMNC Brain Health. "To develop the ABCB1 test together with R-Biopharm is encouraging and an important step to achieve our ambitious goal even faster." Complementary diagnostics are increasingly in demand with the recognition that personalized medicine provides a way to improve patient care and reduce health care costs by matching specific therapies to individuals most likely to benefit from them, since all patients do not respond in the same way. Financial terms of the agreement were not disclosed. Contact: R-Biopharm AG Companion Diagnostics Dr. Frank Apostel, Vice President Business Devlopment An der neuen Bergstraße 17 64297 Darmstadt, Germany Phone: +49 (0) 61 51 - 81 02-537 E-mail: f.apostel@r-biopharm.de www.r-biopharm.com www.companion-diagnostics.com About ABCB1: The ABCB1 gene encodes the P-glycoprotein, which transports various molecules across extra- and intracellular membranes. It functions as transporter for drugs such as antidepressants in the blood-brain barrier. Variants in the ABCB1 gene influence intracerebral concentration of certain antidepressants (e.g., citalopram, paroxetine, amitriptyline, venlafaxine) and thus their efficacy. The ABCB1 test delivers a decision aid for physicians with respect to the type and dosing of antidepressant medication, leading to faster time to remission and higher overall remission rates. About HMNC Brain Health: HMNC Brain Health GmbH (Munich, Germany) is specialized in the development of innovative drug treatments for depression, anxiety, and sleep disorders. The portfolio includes laboratory diagnostics that help to stratify patients according to underlying causal mechanisms and to identify the right drug for the right patient. Early stage projects cover the development of molecules that engage with unprecedented targets and work through novel modes of action. Together with partners from academia and with investors, the company utilizes prominent research results to generate innovative and marketable concepts. About R-Biopharm AG: R-Biopharm AG (Darmstadt, Germany) is a globally active life science company and a leading provider of reliable test systems for clinical diagnostics and for analyzing human food and animal feedstuffs. Since 1988, R-Biopharm has been developing innovative products characterized by top quality, reliability and efficiency. A strong sense of responsibility, long-standing experience and a network more than 20 affiliated companies and subsidiaries in Europe, the US, South America, China and Australia, as well as more than 100 distribution partners, make R-Biopharm a prime partner for clients from retail, industry and public institutions looking for answers and solutions for current analytical challenges. --------------------------------------------------------------------------- 19.04.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------------- 455077 19.04.2016

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

SVRN Taps Industry Vet Patrick O'Kain as COO

SVRN Aims for New Heights with a Savvy Hire If there’s one thing veteran market-watchers like myself know, it’s that leadership shifts can tell you more about a company’s guts than any press release. SVRN (NASDAQ: SVRN), a name with one foot firmly in the world of digital assets, just snagged Patrick O’Kain for their COO spot. They're not playing around, folks,...

Survey Reveals 'TDS' Impact on 2026 Midterm Elections

Midterms and 'Trump Derangement Syndrome': What's the Deal? Every election season there's something new to raise eyebrows, and this time it's 'Trump Derangement Syndrome' (TDS) taking the spotlight. After the dust of the 2026 mid-terms started settling, it turns out there's more than just traditional candidate bickering shaping votes. Can you guess what's driving voters?...

Sempra Shines with Robust Q3 2026 Financials

Strong Q3 Numbers Set the Scene It’s not every day you see a company cough up numbers that speak volumes. Sempra’s third quarter for 2026 paints a picture of solid performance, boasting earnings of $877 million or $1.34 per diluted share per GAAP standards. That’s an eye-opener compared to the paltry $77 million or $0.12 per share they reported same time last year....

Coastal Financial Faces Class Action Suit Over Securities

Securities Law Tangles: Coastal Financial Hits a Snag There's no dodging it—Coastal Financial Corporation's dogged by a class action lawsuit, and investors need to sit up and take notice. This kind of legal fracas can hit the stock price like a brick through a window, especially when alleged securities law violations crop up. DJS Law Group's got the reins on this one,...

Grant Davis Joins Assembly Health as CXO

By Olivia Taylor Updated Nov 4, 2026 Category News Views 101

Shuffling Pieces in Healthcare Management Change is constant in healthcare management, folks, and it's all about finding the right puzzle pieces. That's what Assembly Health has done by welcoming Grant Davis as their new Chief Experience Officer (CXO). Yeah, you heard me right. It's not a CEO or a CFO, but the CXO role that's under the spotlight this time around, aiming...

MAURE's Three-Year Mark: Crafting Home Elegance

Brooklyn's Gem: MAURE Turns Three Over in Brooklyn, there's a brand bubbling with style called MAURE. Now, we're talking three years strong, surviving the wild bout of the retail scene with a firm two feet planted in home and gifting. The Vision Turned Reality When Maureen Cavalieri, a hospitality veteran since 2009, first tossed this spark into the wind in 2023, it...

Dizal Unveils Promising Data at ASH 2026

Pushing the Horizons in Hematological Research From the bustling streets of Shanghai to the global stage of the ASH 2026, Dizal has made its mark again. This year's presentations could very well shake up the hematological landscape, showcasing new possibilities for treatment strategies. Golidocitinib: A Game-Changer? Now here's a ticket we've been watching with some high...

LOA Roofing's Growth Recap Taps Southstone's Backing

Pardon my skepticism, but when a roofing company names itself Life of Abundance, you know they're aiming to hit it big or at least make you think they're onto something special. LOA Roofing and Construction, holding its ground as a major player in the Central Texas market, set the stage for more ambitious growth. And they found themselves a dance partner in Southstone...

SKF's Industrial Push: Energy Efficiency at COP31

SKF's Green Initiative: A Major Step Forward You ever find yourself in a room full of big players, each trying to outdo the other? That's the stage set for SKF at COP31, where they're not just strutting around showing off but actually offering some substance—a rarity in these highbrow gatherings. They're juicing up the talk around energy efficiency and circularity...

Eli Lilly's Retatrutide Trials Signal Innovation

Unpacking Lilly's Latest Rheumatology Innovations Lilly's taking the stage at ACR Convergence 2026 with a potent arsenal of data that’s got folks buzzing. The company’s put the pedal to the metal on understanding the intertwining chords of obesity and rheumatologic conditions, and boy, are they not messing around. Retatrutide: A Triple Threat in the Making Headlining...